While biotech stocks saw an early selloff Friday, the shares of three companies in the sector have plenty of potential left, John Schroer of Allianz Global Investors said on CNBC.Biogen Idec is his top pick.”Leading company in the [multiple sclerosis] space. They have some very strong earnings growth, 20 to 25 percent earnings growth over the next three years. And […]
On CNBC’s “Halftime Report,” Siegel said he estimated fair market value for the Dow to be 18,000, adding that the run-up was likely to surpass that point in 2014. “Bull markets usually carry 10 to 20 percent beyond that,” he said, referring to fair market value. “I’m not going to say that that’s going to happen this […]
On CNBC’s “Halftime Report,” Pachter, who had a “neutral” rating on Twitter stock, said he expected the company to improve revenues. “We modeled it to double in size in about five years, and if it does that, I’m optimistically at about $37,” he said. “If it doubles faster, then it’s probably worth what it’s trading at and […]
